전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
preprečevanje kardiovaskularnih bolezni
each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
ocenjevanje kardiovaskularnih (kv) dogodkov
evaluation of cardiovascular (cv) events
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
poročila o mace v študiji kardiovaskularnih izidov
mace reported in cardiovascular outcomes study
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
pri živalih atosiban ni imel kardiovaskularnih učinkov.
in animals atosiban did not exhibit cardiovascular effects.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
kardiovaskularnih dogodkov, ki so odvisni od odmerka,
increased risk of serious cv events,
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
v primeru hudih kardiovaskularnih obolenj moramo biti previdni.
in case of severe cardiovascular disease, care should be taken.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
aklidinijev bromid in tveganja izbranih kardiovaskularnih opazovanih dogodkov.
and the risk of selected cardiovascular endpoints.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
primarni kombinirani dogodki miokardni infarkt smrt zaradi kardiovaskularnih vzrokov
n=4,645
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
za preprečevanje kardiovaskularnih težav je priporočeni odmerek 80 mg enkrat dnevno.
for the prevention of cardiovascular problems, the recommended dose is 80 mg once a day.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
opis in upravljanje venskih in arterijskih trombemboličnih dogodkov kardiovaskularnih dogodkov in periferne nevropatije
description and management of venous and arterial thromboembolic events, cardiovascular events, and peripheral neuropathy
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
delež kardiovaskularnih trombotičnih dogodkov se pri uporabi etorikoksiba in diklofenaka ni pomembneje razlikoval.
there was no significant difference between etoricoxib and diclofenac in the rate of cardiovascular thrombotic events.
마지막 업데이트: 2012-04-11
사용 빈도: 4
품질:
zmanjševanje tveganja kardiovaskularnih dogodkov pri bolnikih s stabilno koronarno arterijsko boleznijo «.
reduction of risk of cardiovascular events in patients with stable coronary artery disease”.
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
poleg zgoraj navedenih kriterijev je za presojanje bolnikovih kardiovaskularnih funkcij potrebno klinično mnenje.
in addition to the above criteria, clinician judgement must be exercised in the evaluation of the patient’s cardiovascular functions.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
po epidemioloških izsledkih je večja incidenca kardiovaskularnih pojavov povezana z določenimi pokazatelji, npr.:
according to epidemiological findings, a higher incidence of cardiovascular events has been associated with certain indicators, for instance: − age − elevated heart rate or blood pressure − persistent or recurrent ischemic cardiac pain − marked ecg changes (in particular st-segment abnormalities) − raised cardiac enzymes or markers (e. g.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
pri kuncih, ki so dobivali etorikoksib, so opazili majhno od odmerka neodvisno pojavnost kardiovaskularnih malformacij.
a non-dose-related low incidence of cardiovascular malformations was observed in etoricoxib-treated rabbits.
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
guidant je podjetje s sedežem v zda, ki je dejavno na področju načrtovanja in razvoja kardiovaskularnih medicinskih proizvodov.
guidant is a company incorporated in the united states of america (usa) that is active in the design and development of cardiovascular medical products.
마지막 업데이트: 2014-11-06
사용 빈도: 1
품질:
kohortna študija varnosti zdravila po pridobitvi dovoljenja za promet za inhaliran aklidinijev bromid in tveganja izbranih kardiovaskularnih opazovanih dogodkov.
post-authorisation safety (pas) cohort study of inhaled aclidinium bromide and the risk of selected cardiovascular endpoints.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
ker selektivni zaviralci cox-2 nimajo antiagregacijskega delovanja, niso nadomestilo za acetilsalicilno kislino v profilaksi kardiovaskularnih trombemboličnih bolezni.
cox-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effect.
마지막 업데이트: 2017-04-26
사용 빈도: 5
품질:
selektivni zaviralci cox- 2 ne vplivajo na antitrombocitno delovanje, zato niso nadomestilo za acetilsalicilno kislino v profilaksi kardiovaskularnih trombembolicnih bolezni.
cox-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
te reakcije se lahko pokažejo v obliki kardiovaskularnih, respiratornih ali kožnih reakcij (glejte poglavje 4. 8).
hypersensitivity allergoid and other idiosyncratic reactions may occur with all contrast media for intravenous application, also with gadoversetamide, which could become manifest in form of cardiovascular, respiratory and skin reactions (see section 4.8).
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.